ANANDIE VAN DEN BERG
Default profile image
N/A LE ROUX

Blog #10

10 Apr 2021, 12:44 Publicly Viewable
  1. Dopamine agonists and MOA-B inhibitors.
  2. Amantadine is a NMDA-antagonist that has anti-dyskinetic effects.
  3. MOA-B inhibitors inhibit the MOA-B enzyme that metabolizes dopamine that then increases the dopamine stores in neurons and inhibits the uptake of dopamine in the neurons.
  4. Ergot derivative: bromocriptine. Non-ergot derivatives: ropinirole, pramipexole and apomorphine.
  5. Pramipexole: direct agonist at D3 receptors. Ropinirole: agonist on D2 receptors. Bromocriptine: partial agonist on D2 receptors. Apomorphine: Activates D2-receptors and to a lesser extent D1-receptors.
  6. Rasagiline and selegiline are neuroprotective drugs.
  7. MOA-B inhibitors inhibit the MOA-B enzyme that metabolizes dopamine that then increases the dopamine stores in neurons and inhibits the uptake of dopamine in the neurons.
  8. COMT-inhibitors inhibits the COMT-enzyme that converts L-dopa to 3-O-methyl dopa. 3-O-methyl dopa produces a weak therapeutic response with L-dopa because it competes with L-dopa for the active transport process. Thus, COMT-inhibitors will decrease the metabolism of L-dopa and increases its duration of action.
  9. Istradefyllin is an Adenosine A2a-antagonist. The antagonist interferes with GABA releasing and modulates ACh and dopamine release and will also facilitate dopamine receptor signaling.
  10. Safinamide is used to increase dopamine activity as it is a potent, but reversible, antagonist of MAO-B. It also inhibits dopamine uptake in the neurons and decreases glutamate release.